upto $20 million for brain injury. NYR CEO already stated that the non dilutive funding in the recent webinars will fund phase 2 clinical trials for the company. Plus we have around 4 million dollar R&D coming in next year based off this years trials. So cash will be coming in strong. Safety results and Walter reeed the big catalysts in the short term as per presentation.
NYR Price at posting:
10.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)